RO5459072

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Celiac DiseaseSjogren's Syndrome

Phase 1

A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease

CompletedNCT02679014

Hoffmann-La RocheCeliac Disease

Start: 2016-03-06End: 2016-08-28Updated: 2017-08-25

Phase 2

A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome

CompletedNCT02701985

Hoffmann-La RocheSjogren's Syndrome

Start: 2016-07-05End: 2017-07-10Updated: 2018-08-01

Related Papers

A randomized, double‐blind, placebo‐controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease

Clinical and Translational Science2024-12-311 citations

A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sjögren’s syndrome

Lara D. Veeken2023-03-0230 citations